Survival in dialysis patients is different between patients with diabetes as primary renal disease and patients with diabetes as a co-morbid condition
M. A. Schroijen, Olaf M. Dekkers(Leiden University), Damian Fogarty(Belfast Health and Social Care Trust), Christoph Wanner(Universitätsklinikum Würzburg), Kitty J. Jager(Amsterdam University Medical Centers), F. Jarraya(University of Sfax), Friedrich C. Prischl(Klinikum Wels-Grieskirchen), Marlies Noordzij(University of Amsterdam), Friedo W. Dekker(Leiden University Medical Center), Karl‐Göran Prütz, Moniek W.M. van de Luijtgaarden(Amsterdam UMC Location University of Amsterdam), Pietro Ravani(University of Calgary), T. Leivestad(Oslo University Hospital), Frédéric Collart(French Community of Belgium)
Cited by 43
Related Papers
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
|New England Journal of Medicine|2016|3.6k
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
|The Lancet|2022|1k
Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
|New England Journal of Medicine|2013|990
A single number for advocacy and communication—worldwide more than 850 million individuals have kidney diseases
|Kidney International|2019|886
An introduction to inverse probability of treatment weighting in observational research
|Clinical Kidney Journal|2021|877